Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - The report reviews Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) Overview 7 Therapeutics Development 8 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Stage of Development 8 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Therapy Area 9 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Indication 10 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Companies 14 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 23 CanBas Co Ltd 23 Cascadian Therapeutics Inc 24 Eli Lilly and Company 25 Genentech Inc 26 ProNAi Therapeutics Inc 27 Sareum Holdings Plc 28 Vernalis Plc 29 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Drug Profiles 30 CBP-501 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 CCT-244747 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 FS-105 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 GDC-0575 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 ONT-2409 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 PNT-737 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 prexasertib - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 SAR-020106 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecule to Inhibit Chk1 for Cancer - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecule to Inhibit CHK1 for Oncology - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 V-158411 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Dormant Projects 46 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Discontinued Products 47 Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Featured News & Press Releases 48 Oct 05, 2016: Lilly To Present New Data on Prexasertib At ESMO 2016 48 Sep 22, 2016: New triple therapy could boost treatment and prevent relapse in head and neck cancer 48 May 23, 2016: Clinical Trials of CHK1 Inhibitor CCT245737 to Open at the Royal Marsden Hospital 49 Apr 19, 2016: Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016 50 Apr 05, 2016: CHK1 inhibitor CCT245737 Approved for Clinical Trials in Cancer Patients 51 Feb 01, 2016: CHK1 Clinical Trial Application Submissions 51 Dec 15, 2015: CHK1 Clinical Trial Applications 51 May 12, 2015: Sareum to Present at BioTrinity 2015 52 Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY2606368 at AACR Annual Meeting 2015 52 Apr 17, 2013: CanBas Announces Topline Results From Phase II Trial Of CBP501 In Patients With Non-Small Cell Lung Cancer 53 Jun 04, 2012: CanBas's CBP501 Meets Primary Endpoint In Phase II Study Of Malignant Pleural Mesothelioma 54 Jan 05, 2012: CanBas's CBP501 Receives Orphan Drug Designation From FDA For Malignant Mesothelioma 54 Nov 01, 2011: Canbas Enrolls Last Patient In Phase II Trial Of CBP501 As First-Line Treatment Of Malignant Pleural Mesothelioma 55 Oct 27, 2011: Canbas Announces Last Patient Enrolled In Phase II Trial Of CBP501 As First-Line Treatment Of Non-Small Cell Lung Cancer 55 Jan 20, 2010: New Molecules SAR-020106 Increase The Effectiveness Of Certain Cancer Therapies 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 (Contd..1) 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Pipeline by CanBas Co Ltd, H2 2016 23 Pipeline by Cascadian Therapeutics Inc, H2 2016 24 Pipeline by Eli Lilly and Company, H2 2016 25 Pipeline by Genentech Inc, H2 2016 26 Pipeline by ProNAi Therapeutics Inc, H2 2016 27 Pipeline by Sareum Holdings Plc, H2 2016 28 Pipeline by Vernalis Plc, H2 2016 29 Dormant Projects, H2 2016 46 Discontinued Products, H2 2016 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
